PROTEOMICS FOR HUMAN NEUROPSYCHIATRIC DISEASES/BIOMARKERS FOR NEUROPSYCHIATRIC DISORDER
NOVEMBER 2-3, 2006
MARRIOTT ANNAPOLIS WATERFRONT HOTEL
80 COMPROMISE STREET
ANNAPOLIS, MD21401
THE IMPORTANCE OF BIOMARKERS FOR THE STANLEY MEDICAL RESEARCH INSTITUTE
Michael Knable, The Stanley Medical Research Institute
WHAT WE KNOW AND DON’T KNOW ABOUT SCHIZOPHRENIA AND BIPOLAR DISORDER
E. Fuller Torrey, The Stanley Medical Research Institute
CHARACTERIZATION OF POPULATIONS AND SAMPLE COLLECTIONS
Maree Webster, The Stanley Medical Research Institute
THE STANLEY BRAIN GENOMICS DATABASE
Michael Elashoff, The Stanley Medical Research Institute
STUDIES OF INDIVIDUALS WITH RECENT ONSET AND ESTABLISHED SCHIZOPHRENIA OR BIPOLAR DISORDER
Faith Dickerson, Sheppard Pratt Health System
TESTING GENE-ENVIRONMENT INTERACTIONS IN SCHIZOPHRENIA GENESIS
Vishwajit Nimgaonkar, Western Psychiatric Institute & Clinic
INDIVIDUALS WITH FIRST EPISODE PSYCHOSIS
Marcus Leweke, University of Cologne
THE MILITARY AS A SERO-EPIDEMIOLOGIC LABORATORY: THE MNOPP EXPERIENCE
David Niebuhr, Walter Reed Army Institute of Research
PRENATAL COHORTS, BANKED SERUM AND THE ORIGINS OF SCHIZOPHRENIA: SCIENTIIFIC BREAKTHROUGH OR BUSINESS AS USUAL?
Stephen Buka, BrownUniversity
POPULATION BASED APPROACHES TO THE IDENTIFICATION OF BIOMARKERS AND PREDICTION OF DISEASE
Preban Mortensen, National Centre for Register-based Research, University of Aarhus, Denmark
DISEASE BIOMARKERS IN FIRST-ONSET SCHIZOPHRENIA
Sabine Bahn, University of Cambridge
CSF BIOMARKER DISCOVERY FOR SCHIZOPHRENIA USING PROTEOMIC AND METABOLIC APPROACHES
Jeffrey Huang, University of Cambridge
CONVERGENCE OF BLOOD AND BRAIN GENE EXPRESSION IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Gursharan Chana, University of CaliforniaSan Diego
BIOMARKER PATTERNING WITH MAP TECHNOLOGY TO FACILITATE NOVEL DIAGNOSTIC AND DRUG DEVELOPMENT
Ralph McDade, Rules Based Medicine
FINDING SUBTYPES IN PSYCHOSIS USING GENE EXPRESSION MICROARRAY STUDIES
Kwang Ho Choi, The Stanley Medical Research Institute
EXPOSURE TO INFECTIOUS AGENTS AND INFLAMMATORY RESPONSE IN INDIVIDUALS WITH BIPOLAR DISORDER
Faith Dickerson, Sheppard Pratt Health System
META-ANALYSIS OF 12 GENOMIC STUDIES IN BIPOLAR DISORDER
Michael Elashoff, The Stanley Medical Research Institute
COMPARISON OF SERUM PREPARATION AND OPTIMIZATION METHODS FOR SELDI-TOF-MS
Bogdana Krivogorsky, JohnsHopkinsUniversity, Stanley Division
PATTERNS OF KYNURENINE PATHWAY ACTIVATION AS BIOMARKERS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER
Christine Miller, JohnsHopkinsUniversity, Stanley Division
A CASE-CONTROL STUDY OF ANTIBODIES TO TOXOPLASMA GONDII AND RISK OF SCHIZOPHRENIA AMONG MILITARY PERSONNEL
David Niebuhr, Walter Reed Army Institute of Research
CHRONOTYPES AS BIOMARKERS FOR BIPOLAR DISORDER?
Vishwajit Nimgaonkar, Western Psychiatric Institute and Clinic/UPMC
POLYMORPHISMS IN THE HOMEOBOX GENE OTX2 IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Sarven Sabunciyan, JohnsHopkinsUniversity, Stanley Division
METABOLIC PROFILING OF SERUM FROM SCHIZOPHRENIA PATIENTS: IDENTIFICATION OF POENTIAL DISEASE BIOMARKERS
Emanual Schwarz, University of Cambridge
RIC-3 CONGRUENCE WITH NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT EXPRESSION IS ALTERED IN BIPOLAR DISORDER
Emily Severance, JohnsHopkinsUniversity, Stanley Division
IDENTIFICATION OF PROTEIN ALTERATIONS IN SCHIZPHRENIA: CHANGES IN COFORMATION AND OXIDATIONSTATE
Consuelo Walss-Bass, University of TexasHealthScienceCenter
LIPIDOMIC MAPPING OF ATYPICAL ANTIPSYCHOTIC EFFECTS IN SCHIZOPHRENIA
Rima Kaddurah-Daouk, DukeUniversityMedicalCenter
SEARCHING FOR PROTEIN BIOMARKERS IN SCHIZOPHRENIA
Hung-The Kao, Nathan Kline Institute
NEUROIMMUNE MARKERS AND SCHIZOPHRENIA: WHY ARE WE STILL IGNORING THEM?
Karoly Mirnics, VanderbiltUniversity
THE HUMAN PROTEOME PROJECT
N. Leigh Anderson, Plasma Proteome Institute
MAKING IT SMALL: PROTEIN MICROARRAYS FOR BIOMARKER DISCOVERY
Markus Templin, University of Tuebingen
MULTIPLEX SEROLOGY – A TOOL TO LINK SPECIFIC INFECTIONS AND DISEASE
Michael Pawlita, GermanCancerResearchCenter
QUANTITATIVE PROTEOMICS APPLIED TO BIOMARKER DISCOVERY AND EVALUATION
Bruno Domon, Institute for Molecular Systems Biology, Switzerland
BIOMARKERS FOR BRAIN DISEASE
Lance A. Liotta, GeorgeMasonUniversity
ENHANCING BIOMARKER QUANTIATION: THE INSTRUMENT QUALIFICATION CYCLE
Fiona Plows, Ciphergen Biosystems
A NEW MR AND PROTEOMIC DETECTION METHODS FOR BRAIN MICROHEMORRHAGES – A CAUSE FOR SPORADIC LATE-ONSET DEMENTIA
Wolff Kirsch, Loma Linda University